Myeloma Trial Explores Optimal Induction, Maintenance Regimens

Ariela Katz
Published: Monday, Jul 17, 2017
Shaji Kumar, MD

Shaji Kumar, MD

Two combination regimens anchored by different proteasome inhibitors are being compared in a national clinical trial for patients with newly diagnosed symptomatic multiple myeloma (MM) that also seeks to evaluate the ideal duration of lenalidomide (Revlimid) maintenance therapy.

  The most common adverse events (AEs) associated with bortezomib have been decreases in blood counts, particularly platelet counts; peripheral neuropathy; and increased risk of infections. For carfilzomib, common AEs include drops in blood counts, increased risk of infections, and fatigue. There also was a higher incidence of cardiac failure with the combination of carfilzomib and dexamethasone versus bortezomib and dexamethasone in a previous clinical trial.2 In the head-to-head portion of the ENDURANCE trial, investigators will be closely monitoring patients for these AEs, Kumar said.

The ENDURANCE trial is being sponsored by the ECOG-ACRIN Cancer Research Group, with collaboration from the National Cancer Institute. Bortezomib is developed by Takeda Oncology, and carfilzomib is developed by Amgen Inc.


  1. NCCN clinical practice guidelines in oncology: multiple myeloma version 3.2017. National Comprehensive Cancer network website. Updated November 28, 2016. Accessed July 10, 2017.
  2. Kyprolis [prescribing information]. Thousand Oaks, CA: Onyx Pharmaceuticals, Inc; 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication